U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Castration-resistant prostate carcinoma

MedGen UID:
730224
•Concept ID:
C1328504
•
Neoplastic Process
Synonyms: Castrate-resistant prostate cancer; Castration-resistant prostate cancer; Castration-Resistant Prostate Cancer; Castration-Resistant Prostate Carcinoma; castration-resistant prostate carcinoma; Hormone refractory prostate cancer; Metastatic Castration-Resistant Prostate Carcinoma
SNOMED CT: Hormone refractory prostate cancer (427492003); Castration-resistant prostate cancer (427492003); Castrate-resistant prostate cancer (427492003)
 
Monarch Initiative: MONDO:0850353

Definition

Prostate carcinoma that grows and continues to spread despite the surgical removal of the testes or medical intervention to block androgen production. [from NCI]

Professional guidelines

PubMed

Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J
Crit Rev Oncol Hematol 2015 Nov;96(2):308-18. Epub 2015 Jun 8 doi: 10.1016/j.critrevonc.2015.05.019. PMID: 26100652
Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci 2013 Jun;17(12):1658-64. PMID: 23832735
Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
Pinto A, Cruz P
Drugs R D 2012 Dec 1;12(4):227-33. doi: 10.2165/11636250-000000000-00000. PMID: 23190319Free PMC Article

Recent clinical studies

Etiology

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
Telli T, Tuncel M, Karabulut E, Aksoy S, Erman M, Akdogan B, Caglar M
Prostate 2023 Jun;83(8):792-800. Epub 2023 Mar 15 doi: 10.1002/pros.24518. PMID: 36919876
Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
Adnan A, Basu S
Nucl Med Commun 2021 May 1;42(5):566-574. doi: 10.1097/MNM.0000000000001371. PMID: 33560718
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving (225)Ac-PSMA-617 Radioligand Therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A
J Nucl Med 2020 Jan;61(1):62-69. Epub 2019 May 17 doi: 10.2967/jnumed.119.229229. PMID: 31101746
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Caliò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M
Int J Biol Markers 2017 May 4;32(2):e243-e247. doi: 10.5301/jbm.5000246. PMID: 28085175
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J
Crit Rev Oncol Hematol 2015 Nov;96(2):308-18. Epub 2015 Jun 8 doi: 10.1016/j.critrevonc.2015.05.019. PMID: 26100652

Diagnosis

Differentiation of Discordant Lesions on Dual-Tracer PET/CT ((68)Ga-PSMA-11 and (18)F-FDG) in Prostate Carcinoma: Diagnosis of Second Primary Malignancies.
Chalikandy A, Yadav S, Basu S
J Nucl Med Technol 2023 Dec 5;51(4):339-342. doi: 10.2967/jnmt.123.265779. PMID: 37586854
Extensive colonic pneumatosis. Conservative or Surgical approach?
Pérez Santiago L, Gadea Mateo R, Alfonso Ballester R
Rev Esp Enferm Dig 2020 Aug;112(8):661. doi: 10.17235/reed.2020.6825/2019. PMID: 32496113
Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma.
Soydal C, Nak D, Araz M, Akkus P, Urun Y, Ozkan E, Kucuk NO, Kir MK
Nucl Med Commun 2019 Dec;40(12):1243-1249. doi: 10.1097/MNM.0000000000001106. PMID: 31688499
Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization.
Dyshlovoy SA, Hauschild J, Amann K, Tabakmakher KM, Venz S, Walther R, Guzii AG, Makarieva TN, Shubina LK, Fedorov SN, Stonik VA, Bokemeyer C, Balabanov S, Honecker F, von Amsberg G
Oncotarget 2015 Jul 10;6(19):17328-41. doi: 10.18632/oncotarget.4175. PMID: 26093146Free PMC Article
¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.
McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, Morandeau L
Eur J Nucl Med Mol Imaging 2011 Jan;38(1):14-22. Epub 2010 Sep 23 doi: 10.1007/s00259-010-1579-x. PMID: 20862471

Therapy

Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
Adnan A, Basu S
PET Clin 2022 Oct;17(4):641-652. Epub 2022 Sep 22 doi: 10.1016/j.cpet.2022.07.008. PMID: 36153234
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ, Viglianti BL, Gross MD, Ferretti A, Rubello D, Wong KK
Am J Clin Oncol 2019 Jan;42(1):99-106. doi: 10.1097/COC.0000000000000479. PMID: 30204613
Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol 2014 Feb;73(2):219-22. Epub 2013 Nov 8 doi: 10.1007/s00280-013-2343-2. PMID: 24202668
Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med 2012 Jul-Sep;58(3):203-6. doi: 10.4103/0022-3859.101400. PMID: 23023354
NF-κB signaling in prostate cancer: a promising therapeutic target?
Jain G, Cronauer MV, Schrader M, Möller P, Marienfeld RB
World J Urol 2012 Jun;30(3):303-10. Epub 2011 Nov 16 doi: 10.1007/s00345-011-0792-y. PMID: 22085980

Prognosis

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
Telli T, Tuncel M, Karabulut E, Aksoy S, Erman M, Akdogan B, Caglar M
Prostate 2023 Jun;83(8):792-800. Epub 2023 Mar 15 doi: 10.1002/pros.24518. PMID: 36919876
Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
Adnan A, Basu S
PET Clin 2022 Oct;17(4):641-652. Epub 2022 Sep 22 doi: 10.1016/j.cpet.2022.07.008. PMID: 36153234
Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
Adnan A, Basu S
Nucl Med Commun 2021 May 1;42(5):566-574. doi: 10.1097/MNM.0000000000001371. PMID: 33560718
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving (225)Ac-PSMA-617 Radioligand Therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A
J Nucl Med 2020 Jan;61(1):62-69. Epub 2019 May 17 doi: 10.2967/jnumed.119.229229. PMID: 31101746
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Caliò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M
Int J Biol Markers 2017 May 4;32(2):e243-e247. doi: 10.5301/jbm.5000246. PMID: 28085175

Clinical prediction guides

Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
Telli T, Tuncel M, Karabulut E, Aksoy S, Erman M, Akdogan B, Caglar M
Prostate 2023 Jun;83(8):792-800. Epub 2023 Mar 15 doi: 10.1002/pros.24518. PMID: 36919876
Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
Adnan A, Basu S
PET Clin 2022 Oct;17(4):641-652. Epub 2022 Sep 22 doi: 10.1016/j.cpet.2022.07.008. PMID: 36153234
Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
Adnan A, Basu S
Nucl Med Commun 2021 May 1;42(5):566-574. doi: 10.1097/MNM.0000000000001371. PMID: 33560718
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving (225)Ac-PSMA-617 Radioligand Therapy.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel FL, Van de Wiele C, Morgenstern A
J Nucl Med 2020 Jan;61(1):62-69. Epub 2019 May 17 doi: 10.2967/jnumed.119.229229. PMID: 31101746
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Caliò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M
Int J Biol Markers 2017 May 4;32(2):e243-e247. doi: 10.5301/jbm.5000246. PMID: 28085175

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...